Literature DB >> 19438860

A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.

W-L Di1, R C Hennekam, R E Callard, J I Harper.   

Abstract

BACKGROUND: Loss-of-function mutations in the Kazal-type serine protease inhibitor, LEKTI, encoded by the SPINK5 gene cause the rare autosomal recessive skin disease Netherton syndrome (NS). G1258A polymorphism in SPINK5 may be associated with atopic dermatitis, which shares several clinical features with NS.
OBJECTIVES: To determine if the phenotype of NS can be caused by a single null mutation in SPINK5 combined with the homozygous G1258A polymorphism.
METHODS: We screened mutations in the gene SPINK5 by direct DNA sequencing and position cloning and examined the expressions of the SPINK5-encoded protein LEKTI and other relevant proteins by immunostaining and immunoblot.
RESULTS: We describe here a patient who was clinically diagnosed with NS and carried a single null mutation in SPINK5 combined with the homozygous G1258A polymorphism. SPINK5 mRNA was present at normal levels and LEKTI was expressed in the epidermis. Nonetheless, the putative downstream LEKTI substrates stratum corneum trypsin-like enzyme (SCTE), desmoglein 1 and protein markers of keratinocyte differentiation were expressed abnormally, similar to that seen in NS if two null mutant alleles are present.
CONCLUSION: This finding indicates that haploinsufficiency of SPINK5 can cause the NS phenotype in the presence of one null mutation with homozygous G1258A polymorphisms in SPINK5, and this could impair the function of LEKTI and therefore acts as a true mutation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438860     DOI: 10.1111/j.1365-2133.2009.09231.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.

Authors:  Wei-Li Di; Fernado Larcher; Ekaterina Semenova; Gill E Talbot; John I Harper; Marcela Del Rio; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

Review 2.  Netherton Syndrome: A Genotype-Phenotype Review.

Authors:  Constantina A Sarri; Angeliki Roussaki-Schulze; Yiannis Vasilopoulos; Efterpi Zafiriou; Aikaterini Patsatsi; Costas Stamatis; Polyxeni Gidarokosta; Dimitrios Sotiriadis; Theologia Sarafidou; Zissis Mamuris
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

Review 3.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

4.  Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression.

Authors:  Wei-Li Di; Ekaterina Semenova; Fernando Larcher; Marcela Del Rio; John I Harper; Adrian J Thrasher; Waseem Qasim
Journal:  Hum Gene Ther       Date:  2012-01       Impact factor: 5.695

5.  Intercellular skin barrier lipid composition and organization in Netherton syndrome patients.

Authors:  Jeroen van Smeden; Michelle Janssens; Walter A Boiten; Vincent van Drongelen; Laetitia Furio; Rob J Vreeken; Alain Hovnanian; Joke A Bouwstra
Journal:  J Invest Dermatol       Date:  2013-11-29       Impact factor: 8.551

6.  A novel tumor suppressor SPINK5 targets Wnt/β-catenin signaling pathway in esophageal cancer.

Authors:  Qian Wang; Qin Lv; Hua Bian; Lei Yang; Ke-Lei Guo; Song-Shan Ye; Xue-Feng Dong; Ling-Ling Tao
Journal:  Cancer Med       Date:  2019-03-13       Impact factor: 4.452

Review 7.  SPINKs in Tumors: Potential Therapeutic Targets.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Minglin Zhang; Jie Chen; Xiaolan Li; Linlin Xiao; Jiajia Wang; Qian Long; Jianguo Liu; Xiaoyan Guan
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.